In short
Belinostat is an investigational drug being studied in clinical trials for various types of cancer, including lymphomas, solid tumors, and blood disorders. As a histone deacetylase (HDAC) inhibitor, belinostat works by blocking enzymes involved in cancer cell growth and survival. This article summarizes key findings from clinical trials evaluating belinostat's safety, efficacy, and optimal dosing in different patient populations.
At a glance
- Drug Name
- Belinostat (also known as PXD101, Beleodaq)
- Drug Class
- Histone deacetylase (HDAC) inhibitor
- Administration
- Intravenous infusion, typically over 30 minutes
- Common Dosing
- 1000 mg/m2 on days 1-5 of a 21-day cycle
- Cancer Types Studied
- T-cell lymphomas, solid tumors, myelodysplastic syndromes, hepatocellular carcinoma, B-cell lymphomas
- Key Efficacy Measures
- Objective response rate, progression-free survival, overall survival, duration of response
- Common Side Effects
- Nausea, fatigue, fever, anemia, vomiting, low platelet counts, difficulty breathing
- Special Populations
- Studies ongoing in patients with liver dysfunction to determine appropriate dosing
- Biomarker Studies
- Some trials examining histone acetylation status and gene expression changes
What is Belinostat?
Belinostat is an experimental cancer treatment drug that is being studied for its potential to treat various types of cancer. It is also known by its brand name Beleodaq and was previously referred to as PXD101 in some clinical trials. Belinostat belongs to a class of drugs called histone deacetylase (HDAC) inhibitors.
How Belinostat Works
Belinostat works by helping to turn on genes that limit cell growth and survival of cancer cells. In many tumors, these genes are often switched off, allowing cancer cells to grow uncontrollably. By inhibiting histone deacetylases (HDACs), which are enzymes frequently deregulated in cancer cells, Belinostat can help restore normal cell function and potentially stop or slow down cancer growth.
Conditions Treated with Belinostat
Belinostat is being studied for the treatment of various types of cancer, including:
- T-cell lymphomas: Including peripheral T-cell lymphoma (PTCL) and cutaneous T-cell lymphoma (CTCL)
- B-cell lymphomas: Such as diffuse large B-cell lymphoma and Burkitt lymphoma
- Solid tumors: Various types of solid tumors that have not responded to standard treatments
- Myelodysplastic syndromes (MDS): A group of blood disorders that can lead to leukemia
- Liver cancer: Specifically, hepatocellular carcinoma that cannot be removed by surgery
- Metastatic uveal melanoma: A rare type of eye cancer that has spread to other parts of the body
How Belinostat is Administered
Belinostat is typically administered as an intravenous (IV) infusion, which means it is given directly into a vein. The most common dosing schedule observed in clinical trials is:
- Given once daily for 5 consecutive days
- Followed by a rest period
- This cycle is usually repeated every 21 days
The exact dose and schedule may vary depending on the specific condition being treated and the individual patient's characteristics. For example, in some trials, patients received 1000 mg/m² of Belinostat over a 30-minute infusion on days 1-5 of a 21-day cycle.
Belinostat in Clinical Trials
Belinostat has been and continues to be studied in various clinical trials to determine its safety and effectiveness. These trials have included:
- Phase I trials: To determine the safe dose and identify potential side effects
- Phase II trials: To further evaluate the drug's effectiveness in specific types of cancer
- Combination trials: Studying Belinostat in combination with other drugs, such as Binimetinib for metastatic uveal melanoma
Potential Side Effects
As with any medication, Belinostat can cause side effects. Some of the most common side effects reported in clinical trials include:
- Nausea
- Fatigue
- Fever (pyrexia)
- Anemia (low red blood cell count)
- Vomiting
- Thrombocytopenia (low platelet count)
- Difficulty breathing (dyspnea)
- Neutropenia (low white blood cell count)
- Low potassium levels (hypokalemia)
More serious side effects have also been reported, including pneumonia, blood clots, and changes in kidney function. It's important to discuss all potential risks and side effects with your healthcare provider.
Special Considerations
Researchers are studying how Belinostat affects patients with different levels of liver and kidney function. This is important because Belinostat is processed by the liver, and its safety and effectiveness may be different in patients with liver or kidney problems.
Additionally, some studies are looking at how a patient's genetic makeup might affect their response to Belinostat. For example, variations in a gene called UGT1A1 are being studied to see if they impact how patients process the drug.